Dr. Richard Chin - Top Ten Intellectual Optical Illusions in Clinical Research
I hope this is not too promotional (Dew, no hard feelings if you delete it for being so), but I believe the content of the interview with Dr. Chin is high enough quality to be worthwhile to the board.
Richard Chin is the CEO of The Institute for OneWorld Health, a non-profit biotech that develops medicines for treating diseases afflicting the developing world.
Dr. Chin has overseen over 45 Investigational New Drug (IND) Applications for new molecular entities and new indications, as well as eleven drug registrations.
He was the Senior VP and Head of Global Development at Elan Corporation, where he had worldwide responsibility for Clinical Development, Regulatory, Biostatistics, CMC, QA/Compliance, Safety and Medical Affairs. Dr. Chin has also held various clinical and scientific roles for Genentech, Inc. including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of the drugs at Genentech. He began his career at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director.
Dr. Chin holds the equivalent of a J.D. with honors from Oxford University in England under a Rhodes Scholarship. Dr. Chin holds a Medical Degree from Harvard Medical School and is licensed to practice medicine in California.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.